VP
AKRO

venBio Partners’s Akero Therapeutics AKRO Stock Holding History

venBio Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-596,483
Closed -$20.3M – 8
2022
Q3 		$20.3M Sell
596,483
-1,575,181
-73% -$24.1M 4.7% 5
2022
Q2 		$20.5M Hold
2,171,664
– – 5.84% 7
2022
Q1 		$30.8M Hold
2,171,664
– – 6.83% 6
2021
Q4 		$45.9M Sell
2,171,664
-29,114
-1% -$646K 8.28% 4
2021
Q3 		$49.2M Hold
2,200,778
– – 4.9% 3
2021
Q2 		$54.6M Sell
2,200,778
-243,533
-10% -$6.84M 6.44% 3
2021
Q1 		$70.9M Hold
2,444,311
– – 6.74% 3
2020
Q4 		$63.1M Hold
2,444,311
– – 5.57% 3
2020
Q3 		$75.3M Sell
2,444,311
-705,708
-22% -$24.7M 11.44% 3
2020
Q2 		$78.5M Hold
3,150,019
– – 65.27% 1
2020
Q1 		$66.8M Sell
3,150,019
-790,524
-20% -$17M 56.91% 1
2019
Q4 		$87.5M Sell
3,940,543
-14,315
-0.4% -$296K 37.5% 1
2019
Q3 		$90M Hold
3,954,858
– – 42.68% 1
2019
Q2 		$75.7M Buy
+3,954,858
New +$75M 33.61% 1

Other funds holding AKRO

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

venBio Partners's AKRO Position: Q4 2022 in Review

venBio Partners sold out of Akero Therapeutics (AKRO) in Q4 2022, closing a stake of 596,483 shares — an estimated $20.3M sold.

venBio Partners first reported a position in AKRO in Q2 2019 and held it in 14 quarters. The position peaked at $90M in Q3 2019. 161 funds tracked by Wall St. Rank hold AKRO as of Q4 2022.

  • venBio Partners reported no remaining Akero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • venBio Partners sold 596,483 Akero Therapeutics shares in Q4 2022, an estimated $20.3M.
  • venBio Partners first reported a position in Akero Therapeutics in Q2 2019 and held it in 14 quarters.
  • venBio Partners's Akero Therapeutics position peaked at $90M in Q3 2019.
  • 161 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2022.

Based on venBio Partners's 13F filing for Q4 2022, filed 14 Feb 2023.